References

1. European Cardiovascular Disease Statistics 2008. Available from: http://www.heartstats.org.uk/datapage.asp?id=7683.

2. World Health Organization. Prevalence of overweight and obesity in children and adolescents. Fact sheet 2.3, December 2009. [http://www.euro.who.int/__data/assets/pdf_file/0005/96980/2.3.-Prevalence-of-overweight-and-obesity-EDITED_layouted_V3.pdf]. Accessed 18 April 2011.

3. Tirosh A, Shai I, Afek A et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Eng J Med 2011;364:1315-25.

4. Lawlor DA, Martin RM, Gunnell D et al. Association of body mass index measured in childhood, adolescence, and young adulthood with risk of ischaemic heart disease and stroke: findings from 3 historical cohort studies. Am J Clin Nutr 2006;83:767-73.

5. Osler M, Lund R, Kriegbaum M, Andersen AM. The influence of birwth weight and body mass index in early adulthood on early coronary heart disease risk among Danish men born in 1953. Eur J Epidemiol 2009;24:57-61.

6. Sniderman AD, Williams K, Contois JH et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:doi:10.1161/ciroutcomes.110.959247.

7. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.

8. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25:567-79.

9. Banegas JR, Lopez-Garcia E. Dallongeville J et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe. Eur Heart J 2011; published on-line 15 April.

10. Graham I, Atar D, Borch-Johnsen K, et al; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007;28:2375-414.

11. Murphy AJ, Woollard KJ, Suhartoyo A et al. Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol 2011;31 (published on-line ahead of print).

12. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002;106: 2894–900.

13. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004;44: 1945–56.

14. Shaw JA, Bobik A, Murphy A et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008;103:1084-91.